Lineage Cell Therapeutics Acquires NeuroAirmid, Extends Cash Runway into 2028
Lineage Cell Therapeutics announced the acquisition of NeuroAirmid Therapeutics to add a Huntington's disease program, while extending its cash runway into the second quarter of 2028.
🧠AI AnalysisPhoto: Motley Fool
Key points
- Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics to secure the HUNT1 Huntington's disease program.
- Management updated the company's cash runway guidance into the second quarter of 2028.
- Quarterly revenue declined due to the timing of deferred revenue recognition from its Roche partnership.
Lineage Cell Therapeutics announced the acquisition of NeuroAirmid Therapeutics alongside its third-quarter financial results, adding a new clinical-stage program for Huntington's disease to its pipeline. The move extends the biotech company's projected cash runway into the second quarter of 2028, according to management. Lineage shares fell 7.64% following the update.
The deal brings in HUNT1, a Phase Ib/IIa cell therapy candidate targeting Huntington's disease, completing the company's Lineage 3.0 portfolio strategy alongside its existing OpRegen and OPC1 assets. Management noted that HUNT1 relies on the same proprietary cell line as Lineage's current programs, allowing for immediate integration into its AlloSCOPE manufacturing platform. Meanwhile, quarterly revenue decreased due to the timing of deferred revenue recognition from its ongoing partnership with Roche.
What to watch next: Investors will monitor clinical updates from the Phase Ib/IIa trial of HUNT1 alongside ongoing evaluation of OpRegen in Genentech's Phase IIa study.
Source Motley Fool — fool.com/earnings/call-transcripts/2026/11/13/lineage-lctx-q3-2026-… ↗
Read next
🧠AI AnalysisAnthropic Targets $1.4 Trillion Valuation in Upcoming Nasdaq Debut
AI developer Anthropic is set to list on the Nasdaq with a price range of $70 to $78 per share, potentially valuing the company at $1.4 trillion.
🧠AI AnalysisLowe's Positioned for Growth Amid Expanding Home Remodeling Budgets
An analysis of Lowe's Companies suggests the home improvement retailer is well-positioned to capitalize on increasing consumer spending in the remodeling sector.
💼InvestingExamining OMS Energy Technologies: Balance Sheet Strength and Growth Prospects
OMS Energy Technologies presents an intriguing profile for everyday investors with a robust cash position exceeding $150 million and zero debt.
🧠AI AnalysisNextEra Energy Emerges as Value Opportunity Amid Utility Sector Pullback
Utilities have become closely intertwined with artificial intelligence infrastructure trends, creating potential value plays for everyday investors following recent marke…
🧠AI AnalysisCarlsmed and the Upcoming Reimbursement Reset
An upcoming shift in reimbursement policy for Carlsmed's aprevo device could alter financial forecasts as the market looks beyond pure surgeon adoption.
💼InvestingEvaluating the Risk-Reward Profile of BlackRock MuniHoldings California Quality Fund
The BlackRock MuniHoldings California Quality Fund (MUC) presents a notable yield and discount, though investors should weigh these benefits against the fund's inherent l…